{"count":221415,"next":"https://panelapp-aus.org/api/v1/activities/?format=json&page=394","previous":"https://panelapp-aus.org/api/v1/activities/?format=json&page=392","results":[{"created":"2024-09-11T17:37:09.447758+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2011","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: rnu2-2p has been classified as Green List (High Evidence).","entity_name":"RNU2-2P","entity_type":"gene"},{"created":"2024-09-11T17:35:24.145961+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2010","user_name":"Zornitza Stark","item_type":"entity","text":"gene: RNU2-2P was added\ngene: RNU2-2P was added to Mendeliome. Sources: Literature\nMode of inheritance for gene: RNU2-2P was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted\nPublications for gene: RNU2-2P were set to https://www.medrxiv.org/content/10.1101/2024.09.03.24312863v1\nPhenotypes for gene: RNU2-2P were set to Neurodevelopmental disorder, MONDO:0700092, RNU2-2P-related\nReview for gene: RNU2-2P was set to GREEN\nAdded comment: 15 individuals reported with de novo, recurrent variants in this gene at nucleotide positions 4 and 35. The disorder is characterized by intellectual disability, neurodevelopmental delay, autistic behavior, microcephaly, hypotonia, epilepsy and hyperventilation. All cases display a severe and complex seizure phenotype. \nSources: Literature","entity_name":"RNU2-2P","entity_type":"gene"},{"created":"2024-09-11T17:35:21.345452+10:00","panel_name":"Genetic Epilepsy","panel_id":202,"panel_version":"1.56","user_name":"Zornitza Stark","item_type":"entity","text":"Classified gene: RNU2-2P as Green List (high evidence)","entity_name":"RNU2-2P","entity_type":"gene"},{"created":"2024-09-11T17:35:21.330482+10:00","panel_name":"Genetic Epilepsy","panel_id":202,"panel_version":"1.56","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: rnu2-2p has been classified as Green List (High Evidence).","entity_name":"RNU2-2P","entity_type":"gene"},{"created":"2024-09-11T17:34:35.408651+10:00","panel_name":"Genetic Epilepsy","panel_id":202,"panel_version":"1.55","user_name":"Zornitza Stark","item_type":"entity","text":"Classified gene: RNU2-2P as Green List (high evidence)","entity_name":"RNU2-2P","entity_type":"gene"},{"created":"2024-09-11T17:34:35.376571+10:00","panel_name":"Genetic Epilepsy","panel_id":202,"panel_version":"1.55","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: rnu2-2p has been classified as Green List (High Evidence).","entity_name":"RNU2-2P","entity_type":"gene"},{"created":"2024-09-11T17:33:37.815006+10:00","panel_name":"Genetic Epilepsy","panel_id":202,"panel_version":"1.54","user_name":"Zornitza Stark","item_type":"entity","text":"gene: RNU2-2P was added\ngene: RNU2-2P was added to Genetic Epilepsy. Sources: Literature\nMode of inheritance for gene: RNU2-2P was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted\nPublications for gene: RNU2-2P were set to https://www.medrxiv.org/content/10.1101/2024.09.03.24312863v1\nPhenotypes for gene: RNU2-2P were set to Neurodevelopmental disorder, MONDO:0700092, RNU2-2P-related\nReview for gene: RNU2-2P was set to GREEN\nAdded comment: 15 individuals reported with de novo, recurrent variants in this gene at nucleotide positions 4 and 35. The disorder is characterized by intellectual disability, neurodevelopmental delay, autistic behavior, microcephaly, hypotonia, epilepsy and hyperventilation. All cases display a severe and complex seizure phenotype. \nSources: Literature","entity_name":"RNU2-2P","entity_type":"gene"},{"created":"2024-09-11T17:33:05.394329+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6206","user_name":"Zornitza Stark","item_type":"entity","text":"Marked gene: RNU2-2P as ready","entity_name":"RNU2-2P","entity_type":"gene"},{"created":"2024-09-11T17:33:05.357328+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6206","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: rnu2-2p has been classified as Green List (High Evidence).","entity_name":"RNU2-2P","entity_type":"gene"},{"created":"2024-09-11T17:32:50.840227+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6206","user_name":"Zornitza Stark","item_type":"entity","text":"Classified gene: RNU2-2P as Green List (high evidence)","entity_name":"RNU2-2P","entity_type":"gene"},{"created":"2024-09-11T17:32:50.826035+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6206","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: rnu2-2p has been classified as Green List (High Evidence).","entity_name":"RNU2-2P","entity_type":"gene"},{"created":"2024-09-11T17:31:50.194723+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6205","user_name":"Zornitza Stark","item_type":"entity","text":"gene: RNU2-2P was added\ngene: RNU2-2P was added to Intellectual disability syndromic and non-syndromic. Sources: Literature\nMode of inheritance for gene: RNU2-2P was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted\nPublications for gene: RNU2-2P were set to https://www.medrxiv.org/content/10.1101/2024.09.03.24312863v1\nPhenotypes for gene: RNU2-2P were set to Neurodevelopmental disorder, MONDO:0700092, RNU2-2P-related\nReview for gene: RNU2-2P was set to GREEN\nAdded comment: 15 individuals reported with de novo, recurrent variants in this gene at nucleotide positions 4 and 35. The disorder is characterized by intellectual disability, neurodevelopmental delay, autistic behavior, microcephaly, hypotonia, epilepsy and hyperventilation. All cases display a severe and complex seizure phenotype. \nSources: Literature","entity_name":"RNU2-2P","entity_type":"gene"},{"created":"2024-09-11T15:17:21.193721+10:00","panel_name":"Prepair 1000+","panel_id":3861,"panel_version":"1.287","user_name":"Andrew Coventry","item_type":"entity","text":"reviewed gene: NYX: Rating: GREEN; Mode of pathogenicity: None; Publications: 11062471 11062472 16670814 23714322 34064005 34165036 12506099 11062471 17004930; Phenotypes: Night blindness, congenital stationary (complete), 1A, X-linked MIM310500; Mode of inheritance: X-LINKED: hemizygous mutation in males, biallelic mutations in females","entity_name":"NYX","entity_type":"gene"},{"created":"2024-09-11T14:52:58.863132+10:00","panel_name":"Prepair 1000+","panel_id":3861,"panel_version":"1.287","user_name":"Andrew Coventry","item_type":"entity","text":"reviewed gene: NPHS2: Rating: GREEN; Mode of pathogenicity: None; Publications: 32467597 30260545 24509478 10742096  23242530 24509478 12464671; Phenotypes: Nephrotic syndrome, type 2 MIM#600995; Mode of inheritance: BIALLELIC, autosomal or pseudoautosomal","entity_name":"NPHS2","entity_type":"gene"},{"created":"2024-09-11T14:41:26.152338+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2009","user_name":"Shakira Heerah","item_type":"entity","text":"reviewed gene: PNKP: Rating: GREEN; Mode of pathogenicity: None; Publications: 31436889, 31707899, 20118933, 23224214, 29243230, 2578773, 27066567; Phenotypes: Ataxia-oculomotor apraxia 4, Microcephaly, seizures, and developmental delay, Charcot-Marie-Tooth disease, type 2B2; Mode of inheritance: BIALLELIC, autosomal or pseudoautosomal","entity_name":"PNKP","entity_type":"gene"},{"created":"2024-09-11T14:39:09.302631+10:00","panel_name":"Prepair 1000+","panel_id":3861,"panel_version":"1.287","user_name":"Andrew Coventry","item_type":"entity","text":"reviewed gene: NIPAL4: Rating: GREEN; Mode of pathogenicity: None; Publications: 15317751 17557927 10712205; Phenotypes: Ichthyosis, congenital, autosomal recessive 6 MIM#612281; Mode of inheritance: None","entity_name":"NIPAL4","entity_type":"gene"},{"created":"2024-09-11T14:29:26.480073+10:00","panel_name":"Prepair 1000+","panel_id":3861,"panel_version":"1.287","user_name":"Andrew Coventry","item_type":"entity","text":"reviewed gene: MPLKIP: Rating: GREEN; Mode of pathogenicity: None; Publications: 15645389 16977596; Phenotypes: Trichothiodystrophy 4, nonphotosensitive MIM#234050; Mode of inheritance: BIALLELIC, autosomal or pseudoautosomal","entity_name":"MPLKIP","entity_type":"gene"},{"created":"2024-09-11T14:19:18.288399+10:00","panel_name":"Prepair 1000+","panel_id":3861,"panel_version":"1.287","user_name":"Andrew Coventry","item_type":"entity","text":"reviewed gene: MGAT2: Rating: GREEN; Mode of pathogenicity: None; Publications: 8808595 11228641 22105986 33044030 31420886; Phenotypes: Congenital disorder of glycosylation, type IIa MIM#212066; Mode of inheritance: BIALLELIC, autosomal or pseudoautosomal","entity_name":"MGAT2","entity_type":"gene"},{"created":"2024-09-11T14:17:24.171767+10:00","panel_name":"Prepair 1000+","panel_id":3861,"panel_version":"1.287","user_name":"Cassandra Muller","item_type":"entity","text":"reviewed gene: CTSF: Rating: RED; Mode of pathogenicity: None; Publications: ; Phenotypes: Ceroid lipofuscinosis, neuronal, 13, Kufs type, 615362 (3); Mode of inheritance: BIALLELIC, autosomal or pseudoautosomal","entity_name":"CTSF","entity_type":"gene"},{"created":"2024-09-11T14:09:07.376750+10:00","panel_name":"Prepair 1000+","panel_id":3861,"panel_version":"1.287","user_name":"Andrew Coventry","item_type":"entity","text":"reviewed gene: MCFD2: Rating: AMBER; Mode of pathogenicity: None; Publications: 12717434 17610559 18391077 15886209; Phenotypes: Factor V and factor VIII, combined deficiency of MIM#613625; Mode of inheritance: BIALLELIC, autosomal or pseudoautosomal","entity_name":"MCFD2","entity_type":"gene"},{"created":"2024-09-11T14:05:48.558079+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2009","user_name":"Zornitza Stark","item_type":"entity","text":"Phenotypes for gene: NFU1 were changed from Multiple mitochondrial dysfunctions syndrome 1, MIM# 605711 to Multiple mitochondrial dysfunctions syndrome 1, MIM# 605711; Spastic paraplegia 93, autosomal recessive, MIM# 620938","entity_name":"NFU1","entity_type":"gene"},{"created":"2024-09-11T14:05:26.807479+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2008","user_name":"Zornitza Stark","item_type":"entity","text":"edited their review of gene: NFU1: Changed phenotypes: Multiple mitochondrial dysfunctions syndrome 1, MIM# 605711, Spastic paraplegia 93, autosomal recessive, MIM# 620938","entity_name":"NFU1","entity_type":"gene"},{"created":"2024-09-11T14:04:46.133911+10:00","panel_name":"Hereditary Spastic Paraplegia - paediatric","panel_id":317,"panel_version":"1.84","user_name":"Zornitza Stark","item_type":"entity","text":"Phenotypes for gene: NFU1 were changed from Multiple mitochondrial dysfunctions syndrome 1 (MIM#605711) to Multiple mitochondrial dysfunctions syndrome 1 (MIM#605711); Spastic paraplegia 93, autosomal recessive, MIM# 620938","entity_name":"NFU1","entity_type":"gene"},{"created":"2024-09-11T14:04:06.856630+10:00","panel_name":"Hereditary Spastic Paraplegia - paediatric","panel_id":317,"panel_version":"1.83","user_name":"Zornitza Stark","item_type":"entity","text":"reviewed gene: NFU1: Rating: GREEN; Mode of pathogenicity: None; Publications: ; Phenotypes: Spastic paraplegia 93, autosomal recessive, MIM# 620938; Mode of inheritance: BIALLELIC, autosomal or pseudoautosomal","entity_name":"NFU1","entity_type":"gene"},{"created":"2024-09-11T13:52:20.915892+10:00","panel_name":"Prepair 1000+","panel_id":3861,"panel_version":"1.287","user_name":"Andrew Coventry","item_type":"entity","text":"reviewed gene: LRP5: Rating: GREEN; Mode of pathogenicity: None; Publications: 9056564 9831343 11719191 15346351 18602879; Phenotypes: Exudative vitreoretinopathy 4 MIM#601813, Osteoporosis-pseudoglioma syndrome MIM#259770; Mode of inheritance: BOTH monoallelic and biallelic (but BIALLELIC mutations cause a more SEVERE disease form), autosomal or pseudoautosomal","entity_name":"LRP5","entity_type":"gene"},{"created":"2024-09-11T12:45:19.334767+10:00","panel_name":"Amyloidosis","panel_id":191,"panel_version":"0.27","user_name":"Bryony Thompson","item_type":"panel","text":"Panel name changed from Renal Amyloidosis to Amyloidosis\nHPO terms changed from Renal amyloidosis, HP:0001917 to Renal amyloidosis, HP:0001917; Amyloidosis, HP:0011034\nList of related panels changed from Renal amyloidosis; HP:0001917 to Renal amyloidosis; HP:0001917; Amyloidosis; HP:0011034\nPanel types changed to Victorian Clinical Genetics Services; KidGen; Royal Melbourne Hospital","entity_name":null,"entity_type":null},{"created":"2024-09-11T12:22:36.654494+10:00","panel_name":"Lysosomal Storage Disorder","panel_id":181,"panel_version":"1.13","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: SGMS1 as ready","entity_name":"SGMS1","entity_type":"gene"},{"created":"2024-09-11T12:22:36.633590+10:00","panel_name":"Lysosomal Storage Disorder","panel_id":181,"panel_version":"1.13","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: sgms1 has been classified as Amber List (Moderate Evidence).","entity_name":"SGMS1","entity_type":"gene"},{"created":"2024-09-11T12:22:21.999656+10:00","panel_name":"Lysosomal Storage Disorder","panel_id":181,"panel_version":"1.13","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: SGMS1 as Amber List (moderate evidence)","entity_name":"SGMS1","entity_type":"gene"},{"created":"2024-09-11T12:22:21.979247+10:00","panel_name":"Lysosomal Storage Disorder","panel_id":181,"panel_version":"1.13","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: sgms1 has been classified as Amber List (Moderate Evidence).","entity_name":"SGMS1","entity_type":"gene"},{"created":"2024-09-11T12:20:55.439047+10:00","panel_name":"Lysosomal Storage Disorder","panel_id":181,"panel_version":"1.12","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: SGMS1 as Amber List (moderate evidence)","entity_name":"SGMS1","entity_type":"gene"},{"created":"2024-09-11T12:20:55.422648+10:00","panel_name":"Lysosomal Storage Disorder","panel_id":181,"panel_version":"1.12","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: sgms1 has been classified as Amber List (Moderate Evidence).","entity_name":"SGMS1","entity_type":"gene"},{"created":"2024-09-11T12:17:12.281896+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2008","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: SGMS1 as ready","entity_name":"SGMS1","entity_type":"gene"},{"created":"2024-09-11T12:17:12.263789+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2008","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: sgms1 has been classified as Amber List (Moderate Evidence).","entity_name":"SGMS1","entity_type":"gene"},{"created":"2024-09-11T12:16:42.922346+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2008","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: SGMS1 as Amber List (moderate evidence)","entity_name":"SGMS1","entity_type":"gene"},{"created":"2024-09-11T12:16:42.905330+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2008","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: sgms1 has been classified as Amber List (Moderate Evidence).","entity_name":"SGMS1","entity_type":"gene"},{"created":"2024-09-11T12:14:46.261095+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6204","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: REPS2 as ready","entity_name":"REPS2","entity_type":"gene"},{"created":"2024-09-11T12:14:46.236371+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6204","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: reps2 has been classified as Amber List (Moderate Evidence).","entity_name":"REPS2","entity_type":"gene"},{"created":"2024-09-11T12:14:30.805296+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6204","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: REPS2 as Amber List (moderate evidence)","entity_name":"REPS2","entity_type":"gene"},{"created":"2024-09-11T12:14:30.777528+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6204","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: reps2 has been classified as Amber List (Moderate Evidence).","entity_name":"REPS2","entity_type":"gene"},{"created":"2024-09-11T12:08:33.849503+10:00","panel_name":"Cerebral Palsy","panel_id":73,"panel_version":"1.368","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: REPS2 as ready","entity_name":"REPS2","entity_type":"gene"},{"created":"2024-09-11T12:08:33.832329+10:00","panel_name":"Cerebral Palsy","panel_id":73,"panel_version":"1.368","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: reps2 has been classified as Amber List (Moderate Evidence).","entity_name":"REPS2","entity_type":"gene"},{"created":"2024-09-11T12:08:19.255443+10:00","panel_name":"Cerebral Palsy","panel_id":73,"panel_version":"1.368","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: REPS2 as Amber List (moderate evidence)","entity_name":"REPS2","entity_type":"gene"},{"created":"2024-09-11T12:08:19.238982+10:00","panel_name":"Cerebral Palsy","panel_id":73,"panel_version":"1.368","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: reps2 has been classified as Amber List (Moderate Evidence).","entity_name":"REPS2","entity_type":"gene"},{"created":"2024-09-11T12:07:57.038997+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6203","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: TTL as ready","entity_name":"TTL","entity_type":"gene"},{"created":"2024-09-11T12:07:57.020680+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6203","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: ttl has been classified as Amber List (Moderate Evidence).","entity_name":"TTL","entity_type":"gene"},{"created":"2024-09-11T12:07:51.052845+10:00","panel_name":"Cerebral Palsy","panel_id":73,"panel_version":"1.368","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: REPS2 as Amber List (moderate evidence)","entity_name":"REPS2","entity_type":"gene"},{"created":"2024-09-11T12:07:51.030488+10:00","panel_name":"Cerebral Palsy","panel_id":73,"panel_version":"1.368","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: reps2 has been classified as Amber List (Moderate Evidence).","entity_name":"REPS2","entity_type":"gene"},{"created":"2024-09-11T12:07:19.227434+10:00","panel_name":"Tubulinopathies","panel_id":21,"panel_version":"1.2","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: TTL as ready","entity_name":"TTL","entity_type":"gene"},{"created":"2024-09-11T12:07:19.212940+10:00","panel_name":"Tubulinopathies","panel_id":21,"panel_version":"1.2","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: ttl has been classified as Amber List (Moderate Evidence).","entity_name":"TTL","entity_type":"gene"},{"created":"2024-09-11T12:06:46.195803+10:00","panel_name":"Tubulinopathies","panel_id":21,"panel_version":"1.2","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: TTL as Amber List (moderate evidence)","entity_name":"TTL","entity_type":"gene"},{"created":"2024-09-11T12:06:46.151135+10:00","panel_name":"Tubulinopathies","panel_id":21,"panel_version":"1.2","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: ttl has been classified as Amber List (Moderate Evidence).","entity_name":"TTL","entity_type":"gene"},{"created":"2024-09-11T12:06:33.470725+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6203","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: TTL as Amber List (moderate evidence)","entity_name":"TTL","entity_type":"gene"},{"created":"2024-09-11T12:06:33.456622+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6203","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: ttl has been classified as Amber List (Moderate Evidence).","entity_name":"TTL","entity_type":"gene"},{"created":"2024-09-11T12:06:07.010934+10:00","panel_name":"Tubulinopathies","panel_id":21,"panel_version":"1.2","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: TTL as Amber List (moderate evidence)","entity_name":"TTL","entity_type":"gene"},{"created":"2024-09-11T12:06:06.942773+10:00","panel_name":"Tubulinopathies","panel_id":21,"panel_version":"1.2","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: ttl has been classified as Amber List (Moderate Evidence).","entity_name":"TTL","entity_type":"gene"},{"created":"2024-09-11T12:05:34.316353+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2007","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: REPS2 as ready","entity_name":"REPS2","entity_type":"gene"},{"created":"2024-09-11T12:05:34.283019+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2007","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: reps2 has been classified as Amber List (Moderate Evidence).","entity_name":"REPS2","entity_type":"gene"},{"created":"2024-09-11T12:04:37.285083+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2007","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: TTL as ready","entity_name":"TTL","entity_type":"gene"},{"created":"2024-09-11T12:04:37.264996+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2007","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: ttl has been classified as Amber List (Moderate Evidence).","entity_name":"TTL","entity_type":"gene"},{"created":"2024-09-11T12:04:34.495957+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2007","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: REPS2 as Amber List (moderate evidence)","entity_name":"REPS2","entity_type":"gene"},{"created":"2024-09-11T12:04:34.476739+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2007","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: reps2 has been classified as Amber List (Moderate Evidence).","entity_name":"REPS2","entity_type":"gene"},{"created":"2024-09-11T12:04:00.323508+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2006","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: TTL as Amber List (moderate evidence)","entity_name":"TTL","entity_type":"gene"},{"created":"2024-09-11T12:04:00.292019+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2006","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: ttl has been classified as Amber List (Moderate Evidence).","entity_name":"TTL","entity_type":"gene"},{"created":"2024-09-11T12:03:31.625363+10:00","panel_name":"Mitochondrial disease","panel_id":203,"panel_version":"0.930","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: MRPL42 as ready","entity_name":"MRPL42","entity_type":"gene"},{"created":"2024-09-11T12:03:31.587923+10:00","panel_name":"Mitochondrial disease","panel_id":203,"panel_version":"0.930","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: mrpl42 has been classified as Red List (Low Evidence).","entity_name":"MRPL42","entity_type":"gene"},{"created":"2024-09-11T12:01:31.781634+10:00","panel_name":"Mitochondrial disease","panel_id":203,"panel_version":"0.930","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: MRPL42 as Red List (low evidence)","entity_name":"MRPL42","entity_type":"gene"},{"created":"2024-09-11T12:01:31.765620+10:00","panel_name":"Mitochondrial disease","panel_id":203,"panel_version":"0.930","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: mrpl42 has been classified as Red List (Low Evidence).","entity_name":"MRPL42","entity_type":"gene"},{"created":"2024-09-11T11:59:57.508996+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2005","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: MRPL42 as ready","entity_name":"MRPL42","entity_type":"gene"},{"created":"2024-09-11T11:59:57.482463+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2005","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: mrpl42 has been classified as Red List (Low Evidence).","entity_name":"MRPL42","entity_type":"gene"},{"created":"2024-09-11T11:59:48.545969+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2005","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: MRPL42 as Red List (low evidence)","entity_name":"MRPL42","entity_type":"gene"},{"created":"2024-09-11T11:59:48.513545+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2005","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: mrpl42 has been classified as Red List (Low Evidence).","entity_name":"MRPL42","entity_type":"gene"},{"created":"2024-09-11T11:58:51.016787+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2004","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: MED16 as ready","entity_name":"MED16","entity_type":"gene"},{"created":"2024-09-11T11:58:50.988410+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2004","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: med16 has been classified as Green List (High Evidence).","entity_name":"MED16","entity_type":"gene"},{"created":"2024-09-11T11:57:40.233908+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2004","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: MED16 as Green List (high evidence)","entity_name":"MED16","entity_type":"gene"},{"created":"2024-09-11T11:57:40.220569+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2004","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: med16 has been classified as Green List (High Evidence).","entity_name":"MED16","entity_type":"gene"},{"created":"2024-09-11T11:53:09.817557+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6202","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: GPN2 as ready","entity_name":"GPN2","entity_type":"gene"},{"created":"2024-09-11T11:53:09.799653+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6202","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: gpn2 has been classified as Amber List (Moderate Evidence).","entity_name":"GPN2","entity_type":"gene"},{"created":"2024-09-11T11:51:23.135476+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6202","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: GPN2 as Amber List (moderate evidence)","entity_name":"GPN2","entity_type":"gene"},{"created":"2024-09-11T11:51:23.125112+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6202","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: gpn2 has been classified as Amber List (Moderate Evidence).","entity_name":"GPN2","entity_type":"gene"},{"created":"2024-09-11T11:50:49.177824+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2003","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: GPN2 as ready","entity_name":"GPN2","entity_type":"gene"},{"created":"2024-09-11T11:50:49.153061+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2003","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: gpn2 has been classified as Amber List (Moderate Evidence).","entity_name":"GPN2","entity_type":"gene"},{"created":"2024-09-11T11:50:31.676925+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2003","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: GPN2 as Amber List (moderate evidence)","entity_name":"GPN2","entity_type":"gene"},{"created":"2024-09-11T11:50:31.640247+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2003","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: gpn2 has been classified as Amber List (Moderate Evidence).","entity_name":"GPN2","entity_type":"gene"},{"created":"2024-09-11T11:48:51.040060+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6201","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: FKBP4 as ready","entity_name":"FKBP4","entity_type":"gene"},{"created":"2024-09-11T11:48:51.023097+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6201","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: fkbp4 has been classified as Amber List (Moderate Evidence).","entity_name":"FKBP4","entity_type":"gene"},{"created":"2024-09-11T11:48:46.228743+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6201","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: FKBP4 as Amber List (moderate evidence)","entity_name":"FKBP4","entity_type":"gene"},{"created":"2024-09-11T11:48:46.215965+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6201","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: fkbp4 has been classified as Amber List (Moderate Evidence).","entity_name":"FKBP4","entity_type":"gene"},{"created":"2024-09-11T11:48:08.364377+10:00","panel_name":"Differences of Sex Development","panel_id":99,"panel_version":"0.294","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: FKBP4 as ready","entity_name":"FKBP4","entity_type":"gene"},{"created":"2024-09-11T11:48:08.337740+10:00","panel_name":"Differences of Sex Development","panel_id":99,"panel_version":"0.294","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: fkbp4 has been classified as Amber List (Moderate Evidence).","entity_name":"FKBP4","entity_type":"gene"},{"created":"2024-09-11T11:48:04.882899+10:00","panel_name":"Differences of Sex Development","panel_id":99,"panel_version":"0.294","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: FKBP4 as Amber List (moderate evidence)","entity_name":"FKBP4","entity_type":"gene"},{"created":"2024-09-11T11:48:04.860718+10:00","panel_name":"Differences of Sex Development","panel_id":99,"panel_version":"0.294","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: fkbp4 has been classified as Amber List (Moderate Evidence).","entity_name":"FKBP4","entity_type":"gene"},{"created":"2024-09-11T11:47:16.705779+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2002","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: FKBP4 as ready","entity_name":"FKBP4","entity_type":"gene"},{"created":"2024-09-11T11:47:16.688263+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2002","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: fkbp4 has been classified as Amber List (Moderate Evidence).","entity_name":"FKBP4","entity_type":"gene"},{"created":"2024-09-11T11:47:01.840688+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2002","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: FKBP4 as Amber List (moderate evidence)","entity_name":"FKBP4","entity_type":"gene"},{"created":"2024-09-11T11:47:01.640816+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"1.2002","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: fkbp4 has been classified as Amber List (Moderate Evidence).","entity_name":"FKBP4","entity_type":"gene"},{"created":"2024-09-11T10:57:04.703272+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6200","user_name":"Bryony Thompson","item_type":"entity","text":"Marked gene: EIF3I as ready","entity_name":"EIF3I","entity_type":"gene"},{"created":"2024-09-11T10:57:04.669941+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6200","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: eif3i has been classified as Amber List (Moderate Evidence).","entity_name":"EIF3I","entity_type":"gene"},{"created":"2024-09-11T10:55:37.222719+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6200","user_name":"Bryony Thompson","item_type":"entity","text":"Classified gene: EIF3I as Amber List (moderate evidence)","entity_name":"EIF3I","entity_type":"gene"},{"created":"2024-09-11T10:55:37.197361+10:00","panel_name":"Intellectual disability syndromic and non-syndromic","panel_id":250,"panel_version":"0.6200","user_name":"Bryony Thompson","item_type":"entity","text":"Gene: eif3i has been classified as Amber List (Moderate Evidence).","entity_name":"EIF3I","entity_type":"gene"}]}